Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
about
Prion protein in milkDietary Risk Factors for Sporadic Creutzfeldt-Jakob Disease: A Confirmatory Case-Control Study.Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalopathy models.Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.Optimal haemophilia care versus the reality.Current and future molecular diagnostics for prion diseases.Challenges in the evaluation of safety and efficacy of human tissue and cell based products.Copper and the prion protein: methods, structures, function, and diseaseA review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO.Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.Susceptibility of cell substrates to PrPSc infection and safety control measures related to biological and biotherapeutical products.Factor VIII safety: plasma-derived versus recombinant products.Pharmacotherapy of haemophilia A.Mononucleated Blood Cell Populations Display Different Abilities To Transmit Prion Disease by the Transfusion Route.Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease.Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
P2860
Q33267331-C812EB2B-8E80-4708-81CB-CF4F90918C0BQ33805341-E5559DA2-EF5E-41DA-A8B6-2B2AEF356018Q35826534-A2B4A900-9E8B-4B43-95D2-756512E5A9F4Q36043289-EBF4C6C8-7F1D-4CE8-AC42-F26A5110CF2DQ36399847-F20BE9FB-7EC8-484A-B01C-49C879C60891Q36528891-C1DF00D4-FE6B-4E2A-AEF6-3ACB1C5D8D88Q36572756-E73A3521-8EC5-4ECE-81CB-EF7A8AA60FCDQ36640347-1A67E8E3-34F8-4F72-86D3-8D802168FE94Q36654370-E6FB531D-BBA5-428C-A8AB-1C9233E0F866Q37234113-600247FB-7F77-4C1C-82B7-20EA57947E36Q37375815-FF0D536D-43F7-4AA1-83A5-B59A7135792CQ37882787-48BE40EC-8CCF-444B-B170-4DD69CA09A1AQ37891089-836A0C72-1A31-439B-AE9E-AEF99514BA29Q39063264-84159879-A15B-4942-B307-98A0E0BA4ADCQ39407430-204050D7-6CFD-4734-9357-B4FA2948D9D4Q45868068-E8EA80D4-16A7-4CC4-866E-96D242E37AA8
P2860
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@ast
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@en
type
label
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@ast
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@en
prefLabel
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@ast
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@en
P2860
P1433
P1476
Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
@en
P2093
P2860
P356
10.1111/J.1365-2516.2004.00982.X
P478
10 Suppl 4
P577
2004-10-01T00:00:00Z